Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Scinai Immunotherapeutics Ltd SCNI

Healthcare Biotechnology
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various... see more

Recent & Breaking News (NDAQ:SCNI)

First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial

PR Newswire August 8, 2018

Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors

PR Newswire June 28, 2018

BiondVax Receives Its First €6M Tranche Disbursement From the European Investment Bank (EIB)

PR Newswire June 19, 2018

Factors of Influence in 2018, Key Indicators and Opportunity within BiondVax Pharmaceuticals, MercadoLibre, 1-800 FLOWERS.COM, Redhill Biopharma, Mountain Province Diamonds, and Rhythm Pharmaceuticals — New Research Emphasizes Economic Growth

GlobeNewswire June 5, 2018

BiondVax Announces First Quarter 2018 Financial Results

PR Newswire May 29, 2018

BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update

PR Newswire April 30, 2018

BiondVax to Present at Universal Influenza Vaccines Conference

PR Newswire April 12, 2018

BiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of Its Universal Flu Vaccine in the United States

PR Newswire April 11, 2018

Recent Analysis Shows Norbord, BiondVax Pharmaceuticals, NXP Semiconductors N.V, Lazard, Canadian Solar, and Sierra Wireless Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire April 9, 2018

Recent Analysis Shows KB Financial Group, Southern Missouri, Net 1 UEPS Technologies, Financial Engines, Carbonite, and BiondVax Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire March 15, 2018

BiondVax and European UNISEC Consortium to Host Universal Flu Vaccine Conference

PR Newswire February 8, 2018

BiondVax Universal Flu Vaccine Patent Granted in India

PR Newswire January 2, 2018

BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency (EMA)

PR Newswire December 27, 2017

BiondVax's CEO Issues Letter to Shareholders

PR Newswire December 5, 2017

BiondVax Provides Third Quarter 2017 Financial Results and Update

PR Newswire November 28, 2017

BiondVax and NIH Sign Clinical Trial Agreement for a Phase 2 Trial in the U.S. with BiondVax's Universal Flu Vaccine

PR Newswire November 20, 2017

BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment Option

PR Newswire September 18, 2017

12 Biggest Mid-Day Losers For Thursday

Benzinga.com  September 14, 2017

Mid-Morning Market Update: Markets Mostly Lower; United Natural Foods Profit Beats Expectations

Benzinga.com  September 14, 2017

BiondVax Announces Pricing of Public Offering of American Depositary Shares

PR Newswire September 13, 2017